Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cresco LabsFRA:6CQ -3.20%43 PB Ratio is 0.77 as of Jul. 21, 2026, which is 42% below its 10-year median of 1.32. GuruFocus rates FRA:6CQ with a GF Score™ of 43/100 and a GF Value™ of €0.78 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 921 Drug Manufacturers companies, Cresco Labs ranks better than 81.87% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-21), Cresco Labs's share price is €0.605. Cresco Labs's Book Value per Share for the quarter that ended in Mar. 2026 was €0.79. Hence, Cresco Labs's PB Ratio of today is 0.77.
The historical rank and industry rank for Cresco Labs's PB Ratio or its related term are showing as below:
FRA:6CQ'
s PB Ratio Range Over the Past 10 Years
Min: 0.32 Med: 1.32 Max: 12.33
Current: 0.84
During the past 13 years, Cresco Labs's highest PB Ratio was 12.33. The lowest was 0.32. And the median was 1.32.
FRA:6CQ's PB Ratio is ranked better than 81.87% of 921
companies
in the Drug Manufacturers industry
Industry Median: 1.86
vs FRA:6CQ: 0.84
During the past 12 months, Cresco Labs's average Book Value Per Share Growth Rate was -33.90% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -22.70% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -14.80% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Cresco Labs was 405.60% per year. The lowest was -39.40% per year. And the median was -8.85% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Cresco Labs PB Ratio Related Terms
Cresco Labs PB Ratio Historical Data
* Premium members only.
The historical data trend for Cresco Labs's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cresco Labs's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cresco Labs PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cresco Labs's PB Ratio distribution charts can be found below:
* The bar in red indicates where Cresco Labs's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Cresco Labs's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Cresco Labs (FRA:6CQ) has a PB Ratio of 0.77 as of Jul. 21, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Cresco Labs and its competitors. This is 42% below median its historical median of 1.32. Over the past decade, Cresco Labs' PB Ratio has ranged from 0.32 to 12.33. According to the industry distribution chart, Cresco Labs ranks #167 out of 921 companies in the Drug Manufacturers industry, placing it in the top 18.1%.
Is Cresco Labs' PB Ratio too high?
Cresco Labs' current PB Ratio of 0.77 is 42% below median its 10-year median of 1.32. Over the past 10 years, this metric has ranged from a low of 0.32 to a high of 12.33. The Drug Manufacturers industry median PB Ratio is 1.86. Cresco Labs' value of 0.77 is 58.6% below this industry median. Based on the distribution chart, Cresco Labs ranks #167 out of 921 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Cresco Labs has a GF Score™ of 43/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cresco Labs' PB Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cresco Labs ranks #167 out of 921 companies for PB Ratio. This places Cresco Labs in the top 18% of its industry — outperforming the majority of peers. The industry median PB Ratio is 1.86. Cresco Labs' value of 0.77 is 58.6% below this benchmark. Historically, Cresco Labs' own PB Ratio has ranged from 0.32 to 12.33 over the past decade. While the company's 10-year median is 1.32 vs. the industry median of 1.86, Cresco Labs has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.86, based on 921 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cresco Labs's current PB Ratio of 0.77 is 58.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Cresco Labs and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cresco Labs's current PB Ratio is 0.77, which is 42% below median its own 10-year median of 1.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cresco Labs stock overvalued right now?
Based on GuruFocus' analysis, Cresco Labs (FRA:6CQ) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.78, compared to a current price of €0.61 — trading 22.4% below its estimated fair value. The current PB Ratio is 0.77, which is 42% below median its 10-year median of 1.32 and 58.6% below the Drug Manufacturers industry median of 1.86. Cresco Labs' overall GF Score™ is 43/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Cresco Labs (FRA:6CQ), the current PB Ratio is 0.77 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cresco Labs (FRA:6CQ) Overvalued in 2026?
Based on GuruFocus' analysis, Cresco Labs stock appears to be undervalued.
The current stock price of €0.61 is trading 22.4% below its estimated GF Value™ of €0.78.
GuruFocus considers Cresco Labs to be Modestly Undervalued.
Key valuation signals for FRA:6CQ:
PB Ratio: 0.77 (42% below median its 10-year median of 1.32)
GF Value™: €0.78 vs. price of €0.61 (22.4% below fair value)
Industry Position: 58.6% below the Drug Manufacturers median (#167 of 921)
No single metric tells the full story. See the FRA:6CQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cresco Labs Inc is a vertically-integrated multi-state cannabis operator in the United States licensed to cultivate, manufacture, and sell retail and medical cannabis products through Sunnyside, Cresco Lab's national dispensary brand, and others. The company operates in one segment: the cultivation, manufacturing, distribution, and sale of cannabis. The company's brand includes: Cresco, High Supply, FloraCal Farms, Good News, Wonder Wellness Co., Mindy's, and Remedi.
43GF Score
Get the complete analysis for FRA:6CQ
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6CQ has been successfully added to your 
